帯状疱疹後神経痛治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療タイプ別、流通チャネル別、地域別

帯状疱疹後神経痛（PHN）は、水痘帯状疱疹ウイルス（帯状疱疹）の再活性化による末梢神経の損傷に起因する中程度から重度の神経痛を特徴とします。PHNは帯状疱疹の再活性化後30日以上持続する神経痛です。帯状疱疹後神経痛治療の世界市場は、Pfizer Inc.、Teva Pharmaceutical Industries Ltd.、Mylan N.V.、Endo Pharmaceuticals Inc.などの主要メーカーが主に牽引しており、これらのメーカーは合計で市場収益の50％以上を占めています。これらの大手メーカーは、帯状疱疹後神経痛の治療に対する意識の高まりと、高齢者人口の増加に乗じています。

帯状疱疹後神経痛治療市場では大手ベンダーが優位を占めていますが、特許切れや治療オプションに関連する有効性や効率性の課題により、統合が必ずしも収益性の向上に結びついていません。しかし、帯状疱疹後神経痛治療に対する認識が特に高齢者の間で高まるにつれ、市場力学は進化しています。

世界の帯状疱疹後神経痛治療市場は、帯状疱疹後神経痛の有病率の上昇と高齢者人口の拡大により成長を遂げています。さらに、世界のヘルスケアインフラの整備と帯状疱疹後神経痛治療製品に対する政府の支援が、市場成長の原動力になると予想されます。

帯状疱疹後神経痛治療市場の重要な促進要因は、検診率の上昇と高齢者人口の増加です。米国疾病管理予防センターによると、米国では成人の間で帯状疱疹が増加傾向にあり、約3人に1人が生涯に帯状疱疹を発症するとされています。帯状疱疹の症例のかなりの割合が帯状疱疹後神経痛に至り、特に50歳以上の高齢者に多くなっています。

市場の潜在性にもかかわらず、オピオイド使用に対する懸念と過剰摂取による死亡率の上昇が帯状疱疹後神経痛治療市場に大きな制約を与えています。薬物過剰摂取による死亡のかなりの部分を占めるオピオイド過剰摂取による死亡は、治療選択肢に対する懸念を高めています。

当レポートでは、世界の帯状疱疹後神経痛治療市場について調査し、市場の概要とともに、治療タイプ別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の定義とセグメンテーション
• 市場力学
• バリューチェーン分析
• ポーターのファイブフォース分析
• COVID-19の影響分析
• ウクライナとロシアの紛争の影響
• 経済概要
• PESTLE分析

第3章 世界の帯状疱疹後神経痛治療市場の見通し、2018年～2031年

• 世界の帯状疱疹後神経痛治療市場の見通し、治療タイプ別、金額（10億米ドル）、2018年～2031年
• 世界の帯状疱疹後神経痛治療市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
• 世界の帯状疱疹後神経痛治療市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の帯状疱疹後神経痛治療市場の見通し、2018年～2031年

第5章 欧州の帯状疱疹後神経痛治療市場の見通し、2018年～2031年

第6章 アジア太平洋の帯状疱疹後神経痛治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの帯状疱疹後神経痛治療市場の見通し、2018年～2031年

第8章 中東・アフリカの帯状疱疹後神経痛治療市場の見通し、2018年～2031年

第9章 競合情勢

• 治療タイプと流通チャネルのヒートマップ
• メーカーと流通チャネルのヒートマップ
• 企業の市場シェア分析、2023年
• 競合ダッシュボード
• 企業プロファイル
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Endo Pharmaceuticals Inc.
  • Daiichi Sankyo
  • Acorda Therapeutics
  • Purdue Pharma L.P
  • Teikoku Pharma USA, Inc.
  • Janssen Pharmaceuticals, Inc.

第10章 付録

Post herpetic neuralgia (PHN) is characterized by moderate to severe nerve pain resulting from damage to a peripheral nerve due to the reactivation of the varicella zoster virus (shingles). PHN is nerve pain that persists for more than 30 days after the reactivation of herpes zoster.The global post herpetic neuralgia treatment market is predominantly driven by key players, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc., who collectively account for more than 50% of the market's revenue. These leading manufacturers are capitalizing on growing awareness about post herpetic neuralgia treatment and the increasing geriatric population.

Market Consolidation and Challenges

While large vendors dominate the post herpetic neuralgia treatment market, consolidation hasn't necessarily translated into increased profitability due to patent expirations and the effectiveness and efficiency challenges associated with treatment options. However, the market's dynamics are evolving as awareness about post herpetic neuralgia treatment grows, especially among the elderly.

Drivers of Market Growth

The global post herpetic neuralgia treatment market is experiencing growth due to the rising prevalence of post herpetic neuralgia and the expanding geriatric population. Furthermore, the development of healthcare infrastructure globally, coupled with government support for post herpetic neuralgia treatment products, is expected to drive market growth.

Growing Geriatric Population and Screening Rates

The increasing rates of screening and the growth in the geriatric population are critical drivers of the post herpetic neuralgia treatment market. According to the Center for Disease Control and Prevention, shingles is on the rise among adults in the United States, with approximately 1 in 3 people developing shingles in their lifetime. A significant percentage of shingles cases result in post herpetic neuralgia, particularly in individuals aged 50 and older.

Concerns Over Opioid Use

Despite the market's potential, concerns over opioid use and the rising mortality rates due to overdoses pose significant constraints on the post herpetic neuralgia treatment market. Opioid overdose deaths, accounting for a substantial portion of drug overdose fatalities, have raised concerns over treatment options.

Opportunities in New Drug Development

The development of new drugs presents a significant opportunity in the post herpetic neuralgia treatment market, as a definitive curative treatment is yet to be discovered. Government support for post herpetic neuralgia treatment products, particularly through initiatives and investments in research and development, is expected to foster market growth.

Regional Variations in Market Growth

In developed regions like North America and Europe, the presence of a larger economy, higher purchasing power, and extensive healthcare infrastructure support the growth of the post herpetic neuralgia treatment market. The U.S., in particular, stands out due to excellent reimbursement policies and increasing incidence rates of post herpetic neuralgia. In Asia Pacific, Japan, India, Australia, and New Zealand are key players in the market.

Challenges to Market Realization

Despite the market's potential, challenges remain, particularly related to the efficacy and efficiency of treatment options. While calcium-channel blockers, tricyclic antidepressants, steroids, and opioids are used in post herpetic neuralgia treatment, they have limitations and side effects that restrict their widespread use.

Competitive Analysis

The post herpetic neuralgia treatment market features key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., and others. These players are profiled in the competition section of the report, outlining their market shares, strategies, product offerings, marketing approaches, and company dashboards.

Post Herpetic Neuralgia Treatment Market Segmentation:

The report presents a detailed segmentation of the post-herpetic neuralgia treatment market based on treatment type, distribution channels, and region. The treatment types include drugs, patches, and steroid injectables. Within the drug segment, further subdivisions are made for anticonvulsants, antidepressants, and opioids.

Under the patches segment, there are subdivisions for lidocaine skin patches and capsaicin skin patches. Distribution channels comprise institutional sales, which encompass hospital pharmacies and clinics, and retail sales, which include retail pharmacies, drug stores, and mail-order pharmacies.

The post-herpetic neuralgia treatment market analysis covers regions including North America, Latin America, Europe, Asia Pacific excluding China, China, and the Middle East and Africa.

Table of Contents

1. Executive Summary

• 1.1. Global Post Herpetic Neuralgia Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 3.1. Global Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Drugs
      • 3.1.1.1.1. Anticonvulsants
      • 3.1.1.1.2. Antidepressants
      • 3.1.1.1.3. Opioids
    • 3.1.1.2. Patches
      • 3.1.1.2.1. Lidocaine Patches
      • 3.1.1.2.2. Capsaicin Patches
    • 3.1.1.3. Steroid Injectable
• 3.2. Global Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Institutional Sales
      • 3.2.1.1.1. Hospital Pharmacies
      • 3.2.1.1.2. Clinics
    • 3.2.1.2. Retail Sales
      • 3.2.1.2.1. Retail Pharmacies
      • 3.2.1.2.2. Drug Stores
      • 3.2.1.2.3. Mail Order Pharmacies
• 3.3. Global Post Herpetic Neuralgia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 4.1. North America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Drugs
      • 4.1.1.1.1. Anticonvulsants
      • 4.1.1.1.2. Antidepressants
      • 4.1.1.1.3. Opioids
    • 4.1.1.2. Patches
      • 4.1.1.2.1. Lidocaine Patches
      • 4.1.1.2.2. Capsaicin Patches
    • 4.1.1.3. Steroid Injectable
• 4.2. North America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Institutional Sales
      • 4.2.1.1.1. Hospital Pharmacies
      • 4.2.1.1.2. Clinics
    • 4.2.1.2. Retail Sales
      • 4.2.1.2.1. Retail Pharmacies
      • 4.2.1.2.2. Drug Stores
      • 4.2.1.2.3. Mail Order Pharmacies
• 4.3. North America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 4.3.1.2. U.S. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1.3. Canada Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 4.3.1.4. Canada Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 5.1. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Drugs
      • 5.1.1.1.1. Anticonvulsants
      • 5.1.1.1.2. Antidepressants
      • 5.1.1.1.3. Opioids
    • 5.1.1.2. Patches
      • 5.1.1.2.1. Lidocaine Patches
      • 5.1.1.2.2. Capsaicin Patches
    • 5.1.1.3. Steroid Injectable
• 5.2. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Institutional Sales
      • 5.2.1.1.1. Hospital Pharmacies
      • 5.2.1.1.2. Clinics
    • 5.2.1.2. Retail Sales
      • 5.2.1.2.1. Retail Pharmacies
      • 5.2.1.2.2. Drug Stores
      • 5.2.1.2.3. Mail Order Pharmacies
• 5.3. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.2. Germany Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.3. U.K. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.4. U.K. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.5. France Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.6. France Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.7. Italy Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.8. Italy Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.9. Turkey Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.10. Turkey Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.11. Russia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.12. Russia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.13. Rest of Europe Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.14. Rest of Europe Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Drugs
      • 6.1.1.1.1. Anticonvulsants
      • 6.1.1.1.2. Antidepressants
      • 6.1.1.1.3. Opioids
    • 6.1.1.2. Patches
      • 6.1.1.2.1. Lidocaine Patches
      • 6.1.1.2.2. Capsaicin Patches
    • 6.1.1.3. Steroid Injectable
• 6.2. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Institutional Sales
      • 6.2.1.1.1. Hospital Pharmacies
      • 6.2.1.1.2. Clinics
    • 6.2.1.2. Retail Sales
      • 6.2.1.2.1. Retail Pharmacies
      • 6.2.1.2.2. Drug Stores
      • 6.2.1.2.3. Mail Order Pharmacies
• 6.3. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.2. China Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.3. Japan Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.4. Japan Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.5. South Korea Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.6. South Korea Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.7. India Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.8. India Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.9. Southeast Asia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.10. Southeast Asia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.11. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.12. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 7.1. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Drugs
      • 7.1.1.1.1. Anticonvulsants
      • 7.1.1.1.2. Antidepressants
      • 7.1.1.1.3. Opioids
    • 7.1.1.2. Patches
      • 7.1.1.2.1. Lidocaine Patches
      • 7.1.1.2.2. Capsaicin Patches
    • 7.1.1.3. Steroid Injectable
• 7.2. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Institutional Sales
      • 7.2.1.1.1. Hospital Pharmacies
      • 7.2.1.1.2. Clinics
    • 7.2.1.2. Retail Sales
      • 7.2.1.2.1. Retail Pharmacies
      • 7.2.1.2.2. Drug Stores
      • 7.2.1.2.3. Mail Order Pharmacies
• 7.3. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.2. Brazil Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.3. Mexico Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.4. Mexico Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.5. Argentina Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.6. Argentina Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.7. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.8. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Drugs
      • 8.1.1.1.1. Anticonvulsants
      • 8.1.1.1.2. Antidepressants
      • 8.1.1.1.3. Opioids
    • 8.1.1.2. Patches
      • 8.1.1.2.1. Lidocaine Patches
      • 8.1.1.2.2. Capsaicin Patches
    • 8.1.1.3. Steroid Injectable
• 8.2. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Institutional Sales
      • 8.2.1.1.1. Hospital Pharmacies
      • 8.2.1.1.2. Clinics
    • 8.2.1.2. Retail Sales
      • 8.2.1.2.1. Retail Pharmacies
      • 8.2.1.2.2. Drug Stores
      • 8.2.1.2.3. Mail Order Pharmacies
• 8.3. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.2. GCC Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.3. South Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.4. South Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.5. Egypt Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.6. Egypt Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.7. Nigeria Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.8. Nigeria Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.9. Nigeria Post Herpetic Neuralgia Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.10. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.11. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Treatment Type vs Distribution Channel Heatmap
• 9.2. Manufacturer vs Distribution Channel Heatmap
• 9.3. Company Market Share Analysis, 2023
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Treatment Type Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Teva Pharmaceutical Industries Ltd.
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Treatment Type Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. Mylan N.V.
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Treatment Type Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. Endo Pharmaceuticals Inc.
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Treatment Type Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. Daiichi Sankyo
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Treatment Type Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. Acorda Therapeutics
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Treatment Type Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. Purdue Pharma L.P
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Treatment Type Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development
  • 9.5.8. Teikoku Pharma USA, Inc.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Treatment Type Portfolio
    • 9.5.8.3. Financial Overview
    • 9.5.8.4. Business Strategies and Development
  • 9.5.9. Janssen Pharmaceuticals, Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Treatment Type Portfolio
    • 9.5.9.3. Financial Overview
    • 9.5.9.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations